17β羟基类固醇脱氢酶13和线粒体融合蛋白2在肝细胞癌组织中的表达变化及生物信息学分析

曾钗明; 严茂林; 石益海; 郭太林; 梅爱农; 陈建康; 许桂平; 何晓红

doi:10.3969/j.issn.1001-5256.2019.12.019

17β羟基类固醇脱氢酶13和线粒体融合蛋白2在肝细胞癌组织中的表达变化及生物信息学分析

DOI: 10.3969/j.issn.1001-5256.2019.12.019

1. 福建省立医院干部特诊科
2. 福建省立医院肝胆外科
3. 海军军医大学附属公利医院消化内科

基金项目:

福建省自然科学基金(2017J01244)；福建省卫计委医学创新课题(2018-CX-8)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1092
- HTML全文浏览量: 31
- PDF下载量: 221
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-16
- 出版日期: 2019-12-20

Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

Department of Cadre Diagnosis and Treatment,Fujian Provincial Hospital

Research funding:

摘要

摘要: 目的探索17β羟基类固醇脱氢酶13（HSD17B13）和线粒体融合蛋白2（MFN2）在临床肝细胞癌（以下简称肝癌）组织样本中的表达变化及临床意义;同时采用生物信息学方法,进行目标基因分析。方法选取2017年9月-2018年3月于福建省立医院接受手术治疗的15例肝癌患者,手术后获取肝癌及其周围癌组织进行实验研究。通过实时荧光定量PCR及Western Blot法检测HSD17B13和MFN2基因在肝癌组织和癌旁组织中的表达变化情况,并分析其临床意义。采用单细胞测序数据库、GTEx数据库及TCGA数据库分析HSD17B13和MFN2在肝癌组织中的表达量、肝癌不同分期的表达水平及与肝癌总体生存的关系,并分析二者之间的相关性。符合正态分布的计量资料两组间比较采用t检验,多组间比较采用方差分析;非正态分布的计量资料两组间比较采用Mann-Whitney U检验,多组间比较采用Kruskal-Wallis H检验。采用log-rank检验变量对生存率的影响,Kaplan-Meier法绘制生存曲线。采用Pearson相关分析检验两个变量之间的关系。结果实时荧光定量PCR及Western Blot检测...
- 癌,肝细胞 /
- 孕酮还原酶 /
- 线粒体膜转运蛋白质类 /
- 基因,肿瘤抑制 /
- 计算生物学
Abstract: Objective To investigate the change in the expression of 17-β-hydroxysteroid dehydrogenase 13( HSD17 B13) and mitofusin2( MFN2) in hepatocellular carcinoma( HCC) tissue and its clinical significance,and to analyze target genes by bioinformatics methods.Methods Fifteen HCC patients who received surgical treatment in Fujian Provincial Hospital from September 2017 to March 2018 were enrolled. HCC and adjacent tissues were collected after surgery. Real-time PCR and Western blot were used to measure the change in the expression of HSD17 B13 and MFN2 in HCC and adjacent tissues,and the clinical significance of such change was analyzed. The single cell sequencing database,the GTEx database,and The Cancer Genome Atlas database were used to analyze the expression of HSD17 B13 and MFN2 in HCC tissue and different stages of HCC,as well as its correlation with overall survival of liver cancer. The correlation between the expression of HSD17 B13 and MFN2 was also analyzed. For normally distributed continuous data,the t test was used for comparison between two groups,and an analysis of variance was used for comparison between multiple groups; for non-normally distributed continuous data,the Mann-Whitney U test was used for comparison between two groups,and the Kruskal-Wallis H test was used for comparison between multiple groups. The log-rank test was used to investigate the influence of variables on survival rate,and the Kaplan-Meier method was used for plotting the survival curve. A Pearson correlation analysis was used to investigate the relationship between the two variables. Results Real-time PCR and Western blot showed that compared with the adjacent tissue,the HCC tissue had significantly downregulated expression of HSD17 B13 and MFN2( PCR: t =-2. 467 and-3. 933,P = 0. 020 and 0. 001; Western blot: t =-5. 357 and-5. 771,P = 0. 006 and0. 026). The bioinformatics analysis showed significantly downregulated expression of HSD17 B13 in HCC tissue( P < 0. 05),and the expression of HSD17 B13 decreased with the increase in the stage of HCC( F = 3. 220,P = 0. 023); low expression of HSD17 B13 was associated with poor survival( risk ratio = 0. 630,P = 0. 011); in HCC tissue,the expression of MFN2 was positively correlated with that of HSD17 B13( r = 0. 190,P < 0. 001). Conclusion There is downregulated expression of MFN2 and HSD17 B13 in liver cancer,and MFN2 and HSD17 B13 may be potential tumor suppressor genes with clinical relevance. They may be involved in biological behaviors in the development and progression of liver cancer and may become useful molecular markers for liver cancer screening,clinical classification,and prognosis evaluation and effective targets for the treatment of liver cancer.
- carcinoma,hepatocellular /
- progesterone reductase /
- mitochondrial membrane transport proteins /
- computational biology /
- genes,tumor suppressor

HTML全文

参考文献(19)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.

[3] LEE S,ZHANG C,LIU Z,et al. Network analyses identify liver-specific targets for treating liver diseases[J]. Mol Syst Biol,2017,13(8):938.

[4] WANG X,LIAO X,YANG C,et al. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy[J]. Oncol Rep,2019,41(3):1586-1602.

[5] LI J,KE W,ZHOU Q,et al. Tumour necrosis factor-αpromotes liver ischaemia-reperfusion injury through the PGC-1α/Mfn2 pathway[J]. J Cell Mol Med,2014,18(9):1863-1873.

[6] MANCINI G,PIRRUCCIO K,YANG X,et al. Mitofusin 2 in mature adipocytes controls adiposity and body weight[J]. Cell Rep,2019,27(2):648.

[7] HERNNDEZ-ALVAREZ MI,SEBASTIN D,VIVES S,et al.Deficient endoplasmic reticulum-mitochondrial phosphatidylserine transfer causes liver disease[J]. Cell,2019,177(4):881-895.

[8] WU Y,ZHOU D,XU X,et al. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma[J]. World J Surg Oncol,2016,14(1):179.

[9] CAI M,XU L,SHEN L,et al. Expression of long-chain noncoding RNA FOXN3-AS2 in hepatocellular carcinoma and its effect on proliferation and invasion of hepatoma cells[J]. Chin J Clin Pharmacol Ther,2018,23(11):1246-1251.(in Chinese)蔡民，许浏，沈兰，等．长链非编码RNA FOXN3-AS2在肝癌中的表达及其对肝癌细胞增殖和侵袭的影响[J]．中国临床药理学与治疗学，2018,23(11):1246-1251.

[10] LIU JZ,HU GJ,SHI LL,et al. Notch signaling pathway involved in invasion and migration of liver cancer cells[J]. Clin J Med Offic,2017,45(11):1159-1161.(in Chinese)刘建中，胡广军，时玲玲，等．Notch信号通路参与肝癌细胞侵袭迁移临床机制研究[J]．临床军医杂志，2017,45(11):1159-1161.

[11] WANG C,GONG J,WU H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease[J]. Biomed Rep,2017,7(2):95-104.

[12] ADAM M,HEIKELH,SOBOLEWSKI C,et al. Hydroxysteroid(17β)dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice[J]. FASEB J,2018,32(6):3434-3447.

[13] CHEN J,ZHUO JY,YANG F,et al. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2018,17(3):220-226.

[14] XU G,YANG F,DING CL,et al. Small nucleolar RNA 113-1suppresses tumorigenesis in hepatocellular carcinoma[J].Mol Cancer,2014,13:216.

[15] YU CB,ZHU LY,WANG YG,et al. Systemic transcriptome analysis of hepatocellular carcinoma[J]. Tumour Biol,2016,37(10):13323-13331.

[16] SUN B,KARIN M. Obesity,inflammation,and liver cancer[J]. J Hepatol,2012,56(3):704-713.

[17] CHENG X,ZHOU D,WEI J,et al. Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-expressed mitofusin-2 gene in human colorectal cancer cell lines[J]. Neoplasma,2013,60(6):620-626.

[18] WANG W,LU J,ZHU F,et al. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells[J]. Med Oncol,2012,29(1):70-76.

[19] SONG J,ZHAO W,LU C,et al. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK-Mfn2 signaling pathway[J]. Cancer Cell Int,2019,19:60.

施引文献

资源附件(0)

访问统计